论文信息 - Identification and Characterization of Potential Impurities of Quetiapine Fumarate

Identification and Characterization of Potential Impurities of Quetiapine Fumarate

Seven potential impurities, including by-products, starting materials and intermediates were identified in pharmaceutical substance quetiapine fumarate and characterized by spectroscopic methods (MS, IR, NMR). Based on these methods the structures of the impurities were assigned or confirmed as: impurity I: 2-(phenylthio)aniline; impurity II: phenyl N-[2-(phenylthio)phenyl]carbamate; impurity III: N,N'-bis[2-(phenylthio) phenyl]urea; impurity IV: N-[2-(phenylthio)phenyl]-1-piperazinecarboxamide hydrochloride; impurity V: N,N'-bis[(2-phenylthio)phenyl]-1,4-piperazinedicarboxamide; impurity VI: 11‐(1-piperazinyl) dibenzo[b,f][1,4]thiazepine fumarate; impurity VII: 1,4-bis(dibenzo[b,f][1,4] thiazepin-11-yl)piperazine. Structural elucidation of compounds, proposed MS fragmentation pathway and possible ways of formation of the impurities are also discussed.

[1] V. K. Handa,et al. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate. , 2008, Die Pharmazie.

[2] G. Balogh,et al. The changing role of NMR spectroscopy in off-line impurity identification: A conceptual view , 2006 .

[3] S. Görög. The importance and the challenges of impurity profiling in modern pharmaceutical analysis , 2006 .

[4] J. Rabey,et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia , 2006, Journal of Neurology.

[5] D. J. Burinsky,et al. Mass spectral characterization , 2004 .

[6] L. Tollsten. 2.7 High performance liquid chromatography (HPLC) and related techniques: 2.7.4 HPLC/MS for drug impurity identification , 2000 .

[7] I. Wilson,et al. 2.7.5. HPLC/NMR and related hyphenated NMR methods , 2000 .

[8] E. Richelson. Receptor pharmacology of neuroleptics: relation to clinical effects. , 1999, The Journal of clinical psychiatry.

[9] L. Arvanitis,et al. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.